SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...

LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...

Encellin Inc. has announced the closing of a US$9.9 million financing round that will support the company’s development of its cell encapsulation platform with an initial focus on type 1 diabetes.

In 2020, there were 2.3 million women diagnosed with breast cancer. Deaths related to cancer occur due to metastasis. In most types of solid tumors, spreading happens through collective migration, ...